A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Docetaxel plus prednisone as a first-line chemotherapy ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

Prostate cancer is the most common cancer among men ... with abiraterone acetate, given with prednisone, versus abiraterone acetate and prednisone for the treatment of participants with ...

Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic ...

Ahead of World Cancer Day, we hear from celebrities who have spoken about how a cancer diagnosis can lead to positive life ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in ...

Aurora Pharmaceutical is pleased to announce the availability of EquiCoxib, the FDA-approved generic equivalent of Equioxx® (firocoxib), a non-steroidal anti-inflammatory drug (NSAID) used for pain ...

ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304) ESMO 2024: HARMONY: A Phase II Study of ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.